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Division of Internal Medicine, University Hospital Zurich, Switzerland
Summary
Check-up examinations, or periodic health examinations
(PHEs), have gained in importance during the last decades
and are nowadays among the most common reasons for
consultations in primary care settings. The aim of PHEs
is to identify risk factors and early signs of disease, but
also to prevent future illness by early intervention. There-
fore, each PHE should include counselling, immunisation
and physical examination according to the patient’s age
and gender. However, deciding whether to screen a patient
and choosing the most appropriate screening method can
be challenging for general practitioners. The U.S. Prevent-
ive Service Task Force (USPSTF) provides updated recom-
mendations on different existing preventive care measures
based on relevant literature review. The aim of this review
is to provide an updated statement of recommendations
regarding preventive care measures based mostly on the
guidelines derived from the USPSTF and the Swiss Med-
ical Board. Among the major updates, there is no recom-
mendation anymore to routinely screen for breast cancer
and prostate cancer in asymptomatic adults. Since 2013,
however, the USPSTF recommends annual screening for
lung cancer with low-dose CT in patients aged 55 to 80
years with a smoking history of ≥30 pack years. During
PHEs, the physician should be alert to the patients’ hidden
agendas, which are the reason for one third of all consulta-
tions in primary care.
Key words: periodic health examination; check-up;
screening; counselling; immunisation; hidden agenda
Introduction
Check-up examinations are among the most common reas-
ons for adults to seek medical attention. Between 2002 and
2004, approximately 44 million adults per year underwent
a periodic health examination (PHE) in the United States
[1]. Data from Canada showed that “general medical exam-
ination” was the second most common reason for medical
visits after hypertension, with a total of 10.5 million exam-
inations per year [2]. A check-up examination is defined as
health care motivated by the need to assess general health
and prevent future illness rather than to attend to symptoms
[3]. Other terms, such as PHE, annual physical or prevent-
ive health examination, are often used. However, all these
expressions exclude preventive care provided during other
visits, e.g., due to chronic or acute illness [4].
Historical perspective
In the 19th century the British physician Horace Dobell,
considered to be the father of mass screening in the United
Kingdom, outlined an argument for the periodic exam-
ination of healthy persons [5]. He suggested that PHEs
could be a way to identify “these earliest evasive periods
of defect in the physiological state, and to adopt measures
for their remedy”. However, developments beyond medical
practice were proved to have more influence in promoting
PHEs. In fact, life insurance companies were suddenly in-
terested in using the applicants’ medical history records
and diagnoses to assess their financial risk [6]. Life insur-
ance companies were interested in both one-time exam-
inations for applicants and periodic examinations for ex-
isting policyholders with the aim of decreasing their risk
for death [7]. Their profit motives influenced the concep-
tions of PHE by focusing the examination on physical de-
fects of applicants and policyholders. It was recommen-
ded to take a thorough medical history together with an
extensive physical examination from head to toe, multiple
blood and urine tests, medical imaging and electrocardio-
grams [8]. In 1921 an uncontrolled study by the Metropol-
itan Life Insurance Company reported that policyholders
undergoing a PHE had a 28% reduction in expected mor-
tality within the subsequent 5 years [9]. In 1922 the Amer-
ican Medical Association officially promoted PHEs and
published a detailed manual on the recommended exam-
ination objects and interpretation of results in the follow-
ing year [10]. However, while public acceptance increased,
medical professionals began to question the value of PHEs
moving towards individualised check-up examinations. A
more selective and evidence-based approach according to
an individual’s risk profile was conceptualised rather than
performing complete annual examinations entailing a large
number of laboratory tests. In 1968 the World Health Or-
ganization (WHO) commissioned a comprehensive review
of screening worldwide, which contained ten principles to
be applied before considering screening for a particular dis-
ease [11]. In 1975 Frame and Carson performed a literat-
ure review assessing the accuracy of screening measures
and their impact on altering disease progression and mor-
tality with respect to 36 major medical conditions [12–15].
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In 1979 the Canadian Task Force analysed 78 conditions
and examined the strength of available evidence for the ef-
fectiveness of screening measures in reducing disease-spe-
cific morbidity and mortality [16]. The group introduced
rules of evidence to evaluate the quality of reported data
and subsequently updated its recommendations. Finally, in
1984 the US Preventive Service Task Force (USPSTF), a
panel formed by the US Department of Health and Human
Studies, began to evaluate specific preventive interventions
in 60 medical conditions by using explicit criteria and rules
of evidence. The group published their first recommenda-
tions in 1989 and have issued several updates since then
[17].
Assessing and grading the evidence
The USPSTF provides annual reports to the US Congress
by identifying critical evidence gaps in research related to
clinical preventive services and recommends priority areas
that deserve further examination [18]. The different pre-
ventive care measures are evaluated and ranged in a spe-
cific recommendation grade based on relevant literature re-
view (grades A, B, C, D and I, see tables 1 and 2) [19].
In Switzerland, the Swiss Medical Board (SMB), an inter-
disciplinary group consisting of independent experts from
medicine, law, ethics and economics, was founded in 2011.
The aim of the panel is to assess the cost-effectiveness of
various medical procedures [20].
Further expert committees are responsible for providing
guidelines regarding specific medical fields, such as the
American Diabetes Association (ADA), the American
Thyroid Association (ATA), the European Society of Car-
diology (ESC), the European Society of Hypertension
(ESH) or the Swiss Atherosclerosis Association (AGLA).
This review is mostly based on the USPSTF and SMB re-
commendations, but also on the opinions of other expert
groups.
Elements of a check-up examination
As previously described, the aim of PHEs is to identify risk
factors and early signs of disease and also to prevent future
illness through early intervention. Therefore, the PHE has
to include counselling, immunisation and physical exam-
ination tailored to patient’s age and sex. Another import-
ant component is the so-called “case finding”, which in-
volves screening based on the patient’s known risk factors
in the context of a concomitant disease (e.g., hypertension)
Table 1: Preventive care services recommended for men, as recommended by the USPSTF [111].
Age (y)Primary prevention
16 35 45 50 55 65 75 80
Time intervals Grade
Counselling
Lifestyle At each PHEa C
Smoking At each PHE A
Alcohol At each PHE B
Sexual behaviour At each PHE B
Immunisation
Standard Review at each PHE Swiss guidelinesj
Influenza Yearlyb Swiss guidelinesj
Pneumococcus Oncec Swiss guidelinesj
Cardiovascular disease
Hypertension Every 1–2 y based on BPd A
Lipid disorders Every 5 years A
Diabetes mellitus Every 3ye B
Obesity At each PHEf B
AAA Onceg B
Cancer
Colorectal cancer Colonoscopy every 10yh A
Lung cancer 1x/y with LDCTi B*
Prostate cancer Not recommended
routinelyk
D*
Thyroid disorders Not recommended
routinely
I
Depression at each PHE B
AAA = abdominal aortic aneurysm; BP = blood pressure; LDCT = low-dose computed tomography; PHE = periodic health examination; y = year
* controversial recommendations
a only in targeted patients
b in specific risk populations (patients with chronic disease or immunosuppression) <65y
c only in specific risk populations (patients with chronic disease or immunosuppression)
d every 2 years if BP <120/80 mm Hg, yearly if BP 120–139/80–89 mm Hg
e in patients with other cardiovascular risk factors
f from 6 years old
g in smokers; repeat every 2–3 years if AAA 3–3.9 cm, every 6 months if 4–5.4 cm
h alternatives to colonoscopy: faecal occult blood testing once a year, or sigmoidoscopy every 5 years combined with FOBT every 3 years
i only recommended by the US Preventive Service Task Force, still controverted in Switzerland
j from the Swiss Federal Office of Public Health
k not recommended by the US Preventive Service Task Force, recommended by expert committees
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or a positive family history (e.g., premature coronary heart
disease in a first-degree relative). Furthermore, physicians
need to be aware of “hidden agendas”, as patients often use
PHE as a reason for consultation to raise the issue of a spe-
cific problem that troubles them.
Primary prevention
Counselling and immunisations are the cornerstones of
primary prevention. In fact, when compared with second-
ary or tertiary prevention, these preventive measures are
harmless, and they have been shown to be clearly more
cost-effective [21]. For these reasons, evidence-based
primary prevention should be part of the PHE for all pa-
tients.
Counselling
Lifestyle
Although a healthy lifestyle has been associated with a de-
creased incidence of cardiovascular disease, there is only
a limited health benefit when behavioural counselling is
applied to all patients in primary care settings (Grade C)
[22]. Therefore, the USPSTF recommends intensive life-
style counselling for patients with risk factors for cardi-
ovascular and diet-related chronic disease (Grade B) [23].
Smoking
Physicians have been shown to be in a strategic position to
support their patients in smoking cessation [24]. Although
tobacco use has been reduced worldwide, it still remains an
important cause of morbidity and death, with 9,000 deaths
associated with tobacco consumption each year in Switzer-
land [25, 26]. Therefore, clinicians should provide smoking
cessation interventions for all patients who smoke tobacco
(Grade A) [27]. Several meta-analyses have demonstrated
a strong correlation between the number and the duration
of counselling sessions and the abstinence rate [28]. Inter-
ventions to help patients quit smoking can be based on the
5 A’s, a validated five-step algorithm, in which patients are
asked about their smoking habits, advised to quit smoking,
assessed if they are ready to quit smoking, assisted in their
attempt to quit smoking, and finally arranged for follow-
up counselling sessions after smoking cessation [28]. This
Table 2: Preventive care services for women, as recommended by the USPSTF [111].
Age (y)Primary prevention
16 21 26 45 50 55 65 75 80
Time intervals Grade
Counselling
Lifestyle At each PHEa C
Smoking At each PHE A
Alcohol At each PHE B
Sexual behaviour At each PHE B
Immunisation
Standard Review at each PHE Swiss guidelinesl
Influenza Yearlyb Swiss guidelinesl
Pneumococcus Oncec Swiss guidelinesl
HPV Once (+ revaccination)d Swiss guidelinesl
Cardiovascular disease
Hypertension Every 1–2 y based on BPe A
Lipid disorders Every 5 yearsf A
Diabetes mellitus Every 3 yf B
Obesity At each PHEg B
Cancer
Colorectal cancer Colonoscopy every 10 yh A
Lung cancer 1x/y with LDCTi B*
Cervical cancer Every 3–5 y A
Breast cancer Not recommended
routinelyj
D*
Thyroid disorders Not recommended
routinely
I
Depression At each PHE B
Osteoporosis Maximum every 2 yearsk B
BP = blood pressure; HPV = human papilloma virus; LDCT = low-dose computed tomography; PHE = periodic health examination; y = year
* controversial recommendations
a only in targeted patients
b in specific risk populations (patients with chronic disease or immunosuppression) <65 y
c only in specific risk populations (patients with chronic disease or immunosuppression)
d 1st vaccination possible between 11 and 26 years
e every 2 years if BP<120/80 mm Hg, yearly if BP 120–139/80–89 mm Hg
f only in patients with cardiovascular risk factors
g from 6 years old
h alternatives to colonoscopy: faecal occult blood testing once a year, or sigmoidoscopy every 5 years combined with FOBT every 3 years
i only recommended by the US Preventive Service Task Force, still controverted in Switzerland
j recommended by the US Preventive Service Task Force, not recommended routinely by the Swiss Medical Board
k for patients with risk factors for osteoporosis <45 y
l from the Swiss Federal Office of Public Health
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algorithm can be used for further lifestyle issues, such as
physical inactivity, alcohol misuse and consumption of illi-
cit drugs.
Alcohol use
Alcohol misuse is also one of the most common prevent-
able causes of morbidity and death [29]. It has been shown
that one in five individuals is engaged in unhealthy or risky
alcohol consumption in Switzerland [25]. Various system-
atic reviews showed the efficacy of counselling interven-
tions among patients with alcohol misuse [30, 31]. These
interventions have also been confirmed to be cost-effect-
ive [32]. For these reasons, the USPSTF recommends that
physicians screen all their patients for alcohol misuse, and
provide brief behavioural counselling sessions to reduce
alcohol intake for those who have a risky alcohol con-
sumption (Grade B) [33]. There are various available tools,
the most validated being the ten-item AUDIT (alcohol use
disorders identification test) questionnaire, with the best
sensitivity and specificity for screening unhealthy alcohol
use [34]. The four CAGE (cut-down, annoyed, guilty, eye-
opener) questions are less sensitive for screening the whole
spectrum of alcohol misuse (for example to distinguish al-
cohol misuse from alcohol abuse or dependence), but can
be used to quickly find out if the patient has a problem re-
garding alcohol consumption [35].
Sexual behaviour
As sexually transmitted infections (STIs) are associated
with morbidity and potential complications, the USPSTF
recommends high intensity behavioural counselling inter-
ventions for sexually active patients (Grade B) [36]. In fact,
several meta-analyses have shown that high-intensity beha-
vioural counselling can reduce the incidence of STIs up to
thirty percent [37, 38].
Immunisation
Standard immunisation
Clinicians should assess standard immunisation at periodic
health examinations and, if indicated, proceed to revaccin-
ation. Based on the guidelines of the Swiss Federal Of-
fice of Public Health, patients between twenty-five and
twenty-nine years or patients considering travelling to en-
demic parts of the world should receive a revaccination
against diphtheria, tetanus and pertussis [25]. A revaccina-
tion against diphtheria and tetanus should then be repeated
once at forty-five years and every ten years for patients
over sixty-five years. Vaccination against poliomyelitis,
hepatitis B virus and measles-mumps-rubella should be as-
sessed and completed if necessary.
Immunisation against influenza
Each year, infections with seasonal influenza are respons-
ible for 100,000 to 250,000 medical consultations, 1,000 to
5,000 hospitalisations, and 400 to 1,500 deaths in Switzer-
land, in particular among patients older than 65 years [25].
An annual immunisation of all patients over sixty-five
years of age could significantly reduce the disease burden
and the associated costs. It has been shown that influenza-
associated pneumonia and hospitalisations could be re-
duced by 50% and mortality by 70% in that population with
influenza immunisation [39]. Specific populations should
also be immunised against influenza before 65 years, such
as health care workers, and patients with chronic diseases
(cardiac or pulmonary disease, renal insufficiency, diabetes
mellitus) or immunosuppression (including HIV-infected
individuals).
Immunisation against Streptococcus pneumoniae
In 1993, Gardner et al. showed that pneumococcus im-
munisation could prevent more than 20,000 deaths in the
United States, and that pneumococcal vaccine was used
in only 14% of the cases in which an immunisation was
primarily indicated [40]. Since then, efforts to promote
pneumococcal vaccination have been made, but the burden
of disease still remains very important [41]. Therefore, the
Swiss Federal Office of Public Health recommends im-
munising risk populations with the 13–conjugated-valent
vaccine [25]. The specific risk populations are character-
ised by chronic diseases (cardiac, pulmonary, hepatic, renal
or haematological disorders), neoplasia, transplantation
and immunosuppression (autoimmune disorders, HIV in-
fection, medicine associated immunosuppression, immun-
odeficiency and functional or anatomical asplenia) [25].
Systematic immunisation of patients older than sixty-five
years is not indicated any more.
Immunisation against human papilloma virus
The Swiss Federal Office of Public Health recommends
immunisation against human papilloma virus (HPV) for all
females between eleven and fourteen years, with a revac-
cination between fifteen and nineteen years [25]. Based
on clinical evaluation, immunisation could be administered
until the age of twenty-six years. Both vaccines available
in Switzerland provide protection against HPV-types 16
and 18, responsible for cervical cancer. Only one vaccine
provides immunisation against HPV-types 6 and 11, which
have been associated with genital warts. Recommendations
regarding immunisation against HPV among males to pre-
vent penile or anal cancer and potentially transmission of
the virus are emerging. In fact, the Australian National
HPV Vaccination Program Register has recently recom-
mended immunising young males against HPV [42].
However, systematic vaccination of males is not yet recom-
mended in Switzerland.
Other immunisations
People with a negative history for varicella zoster virus
(VZV) infection under 40 years of age should be actively
immunised against VZV. The immunisation is especially
recommended in women wishing to become pregnant or
in healthcare workers. The Swiss Federal Office of Public
Health recommends immunisation against hepatitis A virus
for patients who have chronic liver disease, who live in en-
demic parts of the world, who use intravenous drugs, who
are in contact with people living in endemic parts or using
intravenous drugs, who work in specific laboratories or as
drainers, and in men who have sex with men [25]. Immun-
isation against tick-borne encephalitis virus is indicated in
people living in endemic parts of the world [25].
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Screening
Screening tests are designed to identify a disease among
asymptomatic individuals. Based on the WHO guidelines,
screening tests should adhere to various principles [11].
First, the condition should be a relevant health issue and
include a latent phase where validated tests can be per-
formed. The screening tests have to be not only economic-
ally acceptable but also in terms of balance of benefits and
harms for the population. Finally, there should be an avail-
able and validated treatment for the diagnosed condition.
Cardiovascular disease
Hypertension
Hypertension is defined as a systolic blood pressure
>140 mm Hg and/or diastolic blood pressure >90 mm Hg
[43]. As controlled hypertension is associated with a risk
reduction of 50% for heart failure, 40% for cerebrovascular
accidents and 25% for myocardial infarction, it is recom-
mended to routinely screen for hypertension in patients 18
years or older (Grade A) [44, 45]. Recommendations con-
cerning the intervals between blood pressure measurements
are unclear. According to expert opinion, blood pressure
should be measured every two years when systolic blood
pressure is <120 mm Hg and diastolic blood pressure is
<80 mm Hg and annually if the systolic and diastolic blood
pressure values are 120–139 mm Hg and 80–89 mm Hg,
respectively [45].
Abdominal aortic aneurysm
Men aged sixty-five to seventy-five years who have ever
smoked should be screened once for abdominal aortic an-
eurysm (AAA) by ultrasonography (Grade B) [46]. Recom-
mendations for men who have never smoked are unclear
(Grade C). Routine screening for AAA in women is not re-
commended by the USPSTF (Grade E). A surgical inter-
vention is required if an AAA ≥5.5 cm is diagnosed. Ul-
trasonography should be repeated in a two to three year
interval for AAA of 3 to 3.9 cm, and every 6 months for
those with a diameter from 4 to 5.4 cm [46, 47].
Obesity
Prevalence of obesity has increased by 10% to 40% in
Europe during the last decade among both adults and chil-
dren [25]. Obesity, defined as a body-mass-index (BMI)
>30.0 kg/m2 (in children defined as age and genderspecific
BMI at ≥95th percentile) has been associated with an in-
creased risk to develop cardiovascular and cerebrovascular
disease, as well as cancer and diabetes mellitus [48, 49].
A systematic screening for obesity with BMI calculation
is recommended in all patients, beginning at the age of
six years (Grade B) [49, 50]. Patients with a BMI >30
kg/m2 should be offered multimodal behavioural interven-
tions (Grade B), as intensive behavioural counselling has
been shown to reduce weight and cardiovascular risk
factors and to improve glucose tolerance [50]. Time inter-
vals between BMI measurements are still uncertain.
Lipid disorders
Screening for cholesterol disorders is recommended every
five years for men aged thirty-five years or older (Grade
A) and for women with cardiovascular risk factors aged
forty-five years or older (Grade A) [51]. Recommendations
regarding women who are not at increased cardiovascular
risk are not clear (Grade C) [51]. However, screening
guidelines concerning lipid disorders differ between expert
groups. AGLA recommends screening for lipid disorders
among all individuals aged forty years or more, regardless
of gender [52]. Based on the AGLA recommendations,
screening for lipid disorders should be repeated every five
years for low-risk patients (ten-year cardiovascular risk
<10%) and every two to five years for intermediate-risk pa-
tients (ten-year cardiovascular risk 10%–20%) [52]. Lipid-
measurement should then be repeated more frequently
based on the clinical situation for patients with a high or
very high risk (ten-year cardiovascular risk >20%, con-
firmed coronary heart disease, atherosclerosis, diabetes
mellitus with end-organ damage such as stroke, coronary
heart disease and nephropathy, or glomerular filtration rate
<60 ml/min/1.73 m2). ESC recommends screening for lipid
disorders in men aged forty years or more, in women aged
fifty years or more or in post-menopausal women, even if
asymptomatic [53].
Several studies have demonstrated a risk reduction of 30%
for developing cardiovascular disease among individuals
with high total or low HDL cholesterol who take statins
[54]. AGLA provides indications to initiate a lipid-lower-
ing therapy based on the different ten-year risk groups. Al-
though there is no upper age limit for screening lipid disor-
ders, the initiation of a statin-therapy among patients older
than seventy-five years of age should be evaluated indi-
vidually [55]. Furthermore, physicians must be aware that
in a high-risk primary prevention setting, a meta-analysis
did not find evidence for the benefit of statin therapy on all-
cause mortality [56].
Osteoporosis
Screening for osteoporosis with bone-densitometry (DXA)
is recommended for all women aged sixty-five years or
older (Grade B) and for younger females with an increased
risk to develop osteoporosis [57]. Routine screening for os-
teoporosis among asymptomatic men without risk factors
is not recommended (Grade I) [57]. The ten-year risk can
be assessed by using the FRAX-instrument (Fracture Risk
Assessment), based on clinical data, such as age, BMI,
family history, tobacco use and alcohol consumption [58].
Lifestyle counselling concerning healthy diet and exercise
promotion is recommended for all post-menopausal wo-
men to prevent bone-loss, whereas pharmacological inter-
vention is indicated among women aged 50 years or older
with a history of vertebral or hip fracture, a femoral or
spine T-score of -2.5 or lower at DXA or a T-score of –1 to
–2.5 together with an elevated FRAX-score [59]. Accord-
ing to the USPSTF, there is currently insufficient evidence
to recommend vitamin D and calcium supplementation in
primary prevention (Grade I) [60].
Depression
All patients should be screened for depression in primary
care settings (Grade B) [61]. There are various available
screening tools, but it has been shown that asking only two
short questions (”Over the past two weeks, have you felt
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down, depressed, or hopeless?” and “Over the past two
weeks, have you felt little interest or pleasure in doing
things?”) may be as effective to screen for depression com-
pared to more elaborated questionnaires [62]. Once depres-
sion is detected, clinicians should apply standard diagnost-
ic criteria to assess the type and severity of depression.
Cancer
Colorectal cancer
All men and women aged fifty to seventy-five years should
undergo screening for colorectal cancer (Grade A) [63].
Screening of people older than eighty-five years is clearly
not indicated (Grade D), whereas screening among those
between seventy-six and eighty-five years should be as-
sessed individually (Grade C) [63]. The USPSTF recom-
mends three possible screening procedures: colonoscopies
every ten years, annual faecal occult blood testing (FOBT),
or sigmoidoscopies every 5 years combined with faecal oc-
cult blood testing every three years. Although colonoscopy
has been shown to have the best sensitivity and specificity,
annual testing for faecal occult blood alone can also sig-
nificantly reduce mortality [64]. Serious complications as-
sociated with colonoscopy occur in 25 cases per 10,000
procedures [65]. The screening method should therefore be
chosen in a decision-sharing context. Moreover, there is
insufficient evidence to recommend computed tomograph-
ic colonography and faecal DNA testing at the moment
(Grade I) [63]. We recommend colonoscopy with the pos-
sibility of an immediate polypectomy as first-choice
screening method, as polyps can evolve into cancer over
the course of years. A population-based observation study
from Switzerland showed that colorectal cancer screening
by colonoscopy markedly reduced not only the incidence
of colorectal cancer but also cancer-related death [66]. Fur-
thermore, Swiss insurance companies cover the costs for
screening colonoscopies since 2013.
Cervical cancer
Cervical cancer is the third most common cause of cancer
in females worldwide [67]. Several observational studies
showed that cervical cytology testing can reduce mortality
due to cervical cancer up to 60% and is associated with
better cure rates [68, 69]. Therefore, screening for cervical
cancer is recommended in all women aged twenty-one to
sixty-five years with Papanicolaou testing (Grade A) [70].
Regarding screening intervals, women between thirty and
sixty-five years of age should be screened every three
years, or every five years if they wish a longer interval
(Grade A). However, screening for cervical cancer is not
indicated in women younger than twenty-one years or older
than sixty-five years with adequate previous testing and no
increased risk for cervical cancer (Grade D) [70].
Case finding and controversies
Although clinical studies were able to provide strong evid-
ence about screening methods to clarify international
guidelines, robust data on benefits and harms regarding
several screening tests are still lacking, and international
recommendations are conflicting.
Cardiovascular
Diabetes
Screening for type 2 diabetes mellitus is recommended in
adults with a sustained blood pressure ≥135/80 mm Hg
(Grade B) [71]. The USPSTF concluded that there was
insufficient evidence to recommend systematic screening
for type 2 diabetes mellitus among adults with blood pres-
sure values ≤135/80 mm Hg (Grade I), because long-term
outcomes are still uncertain. However, ADA recommends
screening for diabetes in asymptomatic adults of any age
with a BMI ≥25 kg/m2 who have at least one additional
risk factor for diabetes (physical inactivity, severe obesity,
high-risk ethnicity, hypertension, low HDL cholesterol or
elevated triglyceride level, haemoglobin-A1c ≥5.7%, im-
paired fasting glucose, women with gestational diabetes
or polycystic ovarian syndrome, positive history for car-
diovascular disease, first-degree relative with diagnosed
diabetes) or among all individuals ≥45 years of age, in
three-year intervals (Grade B) [72]. The validated tests to
screen for diabetes mellitus are haemoglobin A1c (normal
if <5.7%) or fasting blood glucose measurements (normal
if <5.6 mmol/l), and oral glucose tolerance test (normal if
2h-plasma glucose <7.8 mmol/l).
Coronary heart disease
Screening for coronary heart disease (CHD) among asymp-
tomatic adults at low risk for cardiovascular events with
resting or exercise electrocardiography and cardiac com-
puted tomography (CT) is not recommended (Grade D)
[73]. There is insufficient evidence to recommend screen-
ing for patients at intermediate or high risk for CHD events
(Grade I). In order to assess a patient’s risk level, clinicians
may use the Framingham calculator, which provides the pa-
tient’s ten-year risk assessment (high risk if greater than
20%, intermediate risk if 10 to 20%, low risk if less than
10%) or the AGLA risk calculator, respectively [52].
The SMB recently considered that screening for CHD
among patients at intermediate or high risk could be per-
formed with cardiac CT instead of invasive coronary an-
giogram if medical imaging is required [20]. However,
physicians and patients need to be aware that cardiac CT
can lead to incidental findings, as it enables visualisation
of both cardiac and extracardiac structures. Suspicious pul-
monary nodules represent in particular the vast majority of
clinically significant extracardiac incidental findings [74],
and may lead to further potentially invasive procedures,
such as bronchoscopies or needle biopsies. A future chal-
lenge will be to quantify the benefit arising from searching
for extracardiac findings in randomised controlled long-
term studies for both the patient and the health care system
[74]. In the light of the current available data, we therefore
suggest cardiac CT in patients at intermediate risk when the
result is reasonably expected to lead to change in manage-
ment upon reclassification to a lower or higher risk group.
Thyroid disorders
Screening for thyroid dysfunction is subject to controver-
sies worldwide. ATA recommends screening for thyroid
dysfunction by measuring thyroid stimulating hormone
(TSH) every five years among patients thirty-five years of
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age or older, even if they are asymptomatic [75]. Although
prevalence of thyroid dysfunction is high, particularly for
subclinical and overt hypothyroidism (4 and 2%, respect-
ively), the USPSTF concluded that there is insufficient
evidence to recommend or advise against screening with
TSH measurement among asymptomatic adults (Grade I)
[76–78]. However, it has recently been shown that thyroid
dysfunction may be associated with adverse clinical out-
comes even if subclinical. For instance, studies have repor-
ted that subclinical hypothyroidism may be associated with
an increased risk of developing CHD and heart failure, in
particular if TSH ≥10 mU/l [79, 80]. In subclinical hypo-
thyroidism with TSH 5–10 mU/l a reduction of all-cause
mortality was observed whereas for subclinical hyper-
thyroidism all-cause mortality and cardiovascular morbid-
ity were increased, respectively [81]. Nevertheless, further
studies are needed to clarify the benefits of systematic
screening in asymptomatic persons.
Cancer
Lung cancer
As lung cancer is the leading cause of cancer death in the
United States, and as it is associated with a poor outcome if
diagnosed at an advanced stage, the USPSTF recently up-
dated the recommendations regarding screening [82, 83].
In fact, it is recommended since 2013 to proceed to annual
screening for lung cancer with low-dose CT (LDCT) in pa-
tients aged fifty-five to eighty years with a smoking his-
tory of thirty pack-years, who are currently smoking or
have quit smoking within the past fifteen years (Grade B)
[82]. Several studies, including a large randomised, con-
trolled trial, have reported evidence that annual screening
for lung cancer with LDCT among high-risk individuals
can significantly reduce the number of lung cancer-associ-
ated deaths (relative reduction in mortality of 20% [95%
confidence interval 6.8–26.7, p-value = 0.004]) [84]. For
patients who have quit smoking more than fifteen years
ago, or for those with limited life expectancy or contrain-
dications to undergoing curative lung surgery, screening is
not indicated or should be ceased [82]. However, the SMB
recently stated that screening for lung cancer with positron-
emission tomography/CT is not recommended [20].
In this controversial situation, and in the light of the avail-
able data, we only recommend screening for lung cancer
with LDCT if patient and physician are committed to pur-
sue follow-up investigations as detection of abnormalities
often require further evaluation involving needle biopsy
and/ or surgery. We would like to underline, that preven-
tion, rather than screening, is the most effective strategy for
reducing the long-term burden of lung cancer, and doctors
should therefore provide smoking cessation interventions
for all patients who smoke tobacco (see above).
Breast cancer
In past years, screening for breast cancer was recommen-
ded in Switzerland for all women aged fifty to seventy-four
years. In fact, the USPSTF stated in 2009 that screening
mammography is recommended every two years in women
between fifty and seventy-four years of age (Grade B) [85].
Nevertheless, based on the analyses of several random-
ised controlled trials and observational studies conducted
between 1963 and 1991, the SMB changed its guidelines in
December 2013. They concluded that screening for breast
cancer with mammography presented an unfavourable
cost-effective rate [20, 86]. In fact, most studies have
shown that screening for breast cancer was associated with
a limited reduction in mortality. Among 1,000 regularly
screened women, only one to two deaths due to breast can-
cer could be avoided compared with 1,000 women who
were not regularly screened [20, 87]. Furthermore, false
positive results have been associated with unnecessary
complementary investigations, overtreatment and in-
creased psychological burden. These observations lead to
two major recommendations: systematic screening for
breast cancer with mammography is not recommended, and
currently undergoing systematic screening programmes
should be limited in time [20]. As there is a marked differ-
ence between US and Swiss recommendations, physicians
need to clearly explain to the patients what are the poten-
tial harms and benefits of breast cancer screening. The de-
cision to proceed to breast cancer screening or to interrupt
a screening program should be then done in a physician-pa-
tient decision-sharing context.
Prostate cancer
Prostate cancer is the third most common cancer among
men. Its incidence increases with age, especially after fifty
years. Deaths associated with prostate cancer are rare be-
fore the age of sixty years. In fact, 70% of deaths occur
after 75 years of age [88].
Controversies regarding screening for prostate cancer with
Prostate-Specific-Antigen (PSA) lead to major changes in
recommendations worldwide. The SMB and the Swiss
Academy of Medical Sciences declared in 2011 that sys-
tematic screening for prostate cancer with PSA-measure-
ment was not recommended anymore because of the lim-
ited effect of screening on global mortality and specific
mortality, and the potential associated dangers related to
biopsy and treatment [20]. Nevertheless, the Swiss Society
of Urology recommended individualising PSA-based
screening for prostate cancer, and serial measurements in
the following years [89]. The USPSTF also reviewed their
guidelines and currently recommends against systematic
prostate cancer screening based on PSA measurement
(Grade D) [90].
The members of the USPSTF based their recommendations
on the fact that false-positive results are common (13% cu-
mulative risk for at least one false-positive result after four
PSA measurements) and that biopsy due to a false posit-
ive result may occur in 5.5% of cases [91]. Furthermore,
it has been reported that biopsy-related complications are
often encountered (50% have persistent haematospermia,
22% haematuria, 3% fever), and likewise treatment-associ-
ated harms [92]. Studies have shown that radical prostatec-
tomy is associated with a 30% increased absolute risk for
erectile dysfunction and 20% for urinary incontinence in
comparison with a non-invasive attitude after 1 to 10 years.
Radiation therapy is also associated with an increased risk
to develop erectile dysfunction (17% increase in absolute
risk) and bowel dysfunction after 1 to 10 years [93, 94].
Review article: Current opinion Swiss Med Wkly. 2015;145:w14075
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 7 of 11
In conclusion, PSA-based screening for prostate cancer
should not be performed systematically any more. Clini-
cians should individualise their decision to screen for pro-
state cancer and clearly inform their patients on the benefits
and potential harms associated with an eventual false-posit-
ive result [20]. In our opinion, the patient must be engaged
in explicit and informed decision making with their physi-
cian before initiating or continuing prostate cancer screen-
ing.
Hidden agenda
When patients request a check-up, physicians may assume
it is for detection of asymptomatic disease. However, a pro-
spective study has shown that the majority of patients re-
quiring a check-up were motivated by specific symptoms
and health concerns and did not consist of “asymptomatic”
patients who primarily scheduled a consultation for pre-
ventive issues [95]. Patients disclosed their symptoms and
concerns once they were talking directly with the physi-
cian. However, one in three patients had one or more hid-
den agendas leading to the check-up [95]. When patients’
expectations are not met, patient satisfaction is likely to be
decreased, which can lead to reduced adherence to therapy,
increased health care utilisation, more frequent malpractice
litigation, and switching doctors or health plans [96–100].
Being alert to behavioural and verbal cues is important in
order to recognise and identify hidden agendas and to im-
prove the physician-patient relationship.
Do check-up examinations make
sense?
Opponents of check-up consultations state that head-to-toe
examination, accompanied by comprehensive multiphasic
investigation and laboratory screening is outdated. They re-
port that time needed to conduct a PHE is twice the time
needed for a regular medical consultation. They deplore
that unnecessary investigations, which are not based on
evidence, are ordered for healthy individuals [101]. Fur-
thermore, potentially harmful examinations, such as whole-
body CT scanning, are promoted especially when it comes
to exclusive PHEs for managers [102]. The opponents ar-
gue that some preventive care services should be per-
formed during regular physician consultations regarding
case-findings or during acute care visits [101]. They claim
that preventive measures have a more powerful effect when
performed at the occasion of an acute or chronic office visit
rather than at a special check-up visit [103].
Supporters of PHEs argue that these kinds of consultations
might improve two critical elements of care: relationship
building and preventive care [104]. In fact, it might be
difficult for busy general practitioners (GPs) to dedicate
enough time for preventive care as patients consult their
GPs more for specific complaints than for advice on pre-
vention. To fully satisfy the USPSTF recommendations, a
patients’ panel of 2,500 individuals would need 1773 hours
of a physician’s annual time, representing a total of 7.4
hours per working day only to provide preventive care ser-
vices [105]. Thus, longer scheduled visits allow the phys-
icians to carry out preventive measures more frequently
and to obtain a more holistic view on their patients by dis-
cussing their social networks (patients’ families, works and
social lives) [103, 105]. Furthermore, these consultations
provide opportunities to screen for less obvious conditions,
such as depression [61, 104].
Beyond the discussion whether preventive care should be
provided by physicians seeing patients for acute visits or
during PHEs, physicians ask for new methods of prevent-
ive care delivery, as preventive services currently recom-
mended by the USPSTF require an unreasonable amount of
time [105]. They request a clearer focus on which services
can be best provided and by whom [105].
Are check-up examinations harmful?
A recently published Cochrane systematic review con-
cluded that general health examinations were not associ-
ated with an increase or decrease in all-cause mortality
(RR 0.99, [95%CI, 0.95–1.03]) and disease specific mor-
tality [106]. Data were available from 14 randomised con-
trolled trials involving more than 182,000 patients. A total
of 8 trials reported on cardiovascular mortality (RR 1.03,
[95% CI, 0.91–1.17]) with substantial heterogeneity, and
8 trials reported on cancer mortality (RR 1.01, [95% CI,
0.92–1.12]) with moderate heterogeneity. Furthermore, no
effect was found on hospital admission rates, disability,
additional physician visits or absence from work. The re-
view excluded studies which targeted specific diseases or
which evaluated specific tests. This could theoretically un-
derestimate the effect of PHEs on particular conditions.
Moreover, most trials were old, as the earliest article was
published in 1963 and the latest in 1999. During this time
span, there have been many changes in medical practice
such as risk assessment methods and available preventive
drugs. Of the 11,940 deaths that occurred over nine years
of follow-up, the number of healthy individuals who died
from a condition targeted by the screening intervention,
and could therefore have benefited from early detection,
was probably quite low compared to those who died of
causes that the screening intervention did not target effi-
ciently, such as cancer and unintentional injury [3]. Anoth-
er limitation is the scant data on the risks and costs of
PHEs. There is no data on how frequently PHEs lead to a
cascade effect of testing or over-diagnosis [4].
In 2007, a systematic review by Boulware et al. regarding
the value of PHE concluded that patients benefit from
PHEs through its association with improved delivery of
some recommended clinical preventive services and
through reduction of patients’ concerns [103]. The authors
found no harms associated with PHEs and emphasised that
elimination of worry or concerns regarding illness may rep-
resent a powerful motivator for action on the patients’ side
[103].
Besides, many physicians feel that PHEs strengthen the
physician-patient relationship [4, 107, 108]. In fact, in 2005
a survey by Prochazka et al. demonstrated that 94% of GPs
believed that a PHE could improve the physician patient re-
lationship [108]. According to Prochazka and Caverly, time
spent getting to know a patient is time that pays dividends
down the road [4]. They hope that payment system reforms
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will incentivise value over volume and eventually translate
into more time available to establish a healing relationship.
In the meantime, one way for physicians to carve out some
time might be to avoid performing non-beneficial examina-
tions and unnecessary tests, and thereby avoiding the time-
consuming task of chasing down false-positive and incid-
ental findings [4]. New initiatives, such as “Smart Medi-
cine” or “Choosing Wisely”, have been set up in Switzer-
land and in the United States, respectively, and should
eventually help physicians to promote evidence-based tests
performed at PHEs [109, 110].
Funding / potential competing interests: No financial support
and no other potential conflict of interest relevant to this article
were reported.
Correspondence: Lukas Zimmerli, MD, Division of Internal
Medicine, Cantonal Hospital Olten, Baslerstrasse 150, CH-4600
Olten, Switzerland, lukas.zimmerli[at]spital.so.ch
References
1 Mehrotra A, Zaslavsky AM, Ayanian JZ. Preventive health examina-
tions and preventive gynecological examinations in the United States.
Arch Intern Med. 2007;167:1876–83.
2 IMS Health. Top 10 reasons for physician visits in Canada. In, Canadian
disease and therapeutic index; 2009. Available from: ht-
tp://www.stacommunications.com/journals/cpm/2010/04–April-2010/
CPM_035.pdf
3 Sox HC. The health checkup: was it ever effective? Could it be effect-
ive? JAMA. 2013;309:2496–7.
4 Prochazka AV, Caverly T. General health checks in adults for reducing
morbidity and mortality from disease: summary review of primary find-
ings and conclusions. JAMA Intern Med. 2013;173:371–2.
5 Dobell H. Lectures on the Germs and Vestiges of Disease, and on the
Prevention of the Invasion and Fatality of Disease by Periodical Exam-
inations. London: Churchill; 1861.
6 Han PK. Historical changes in the objectives of the periodic health ex-
amination. Ann Intern Med. 1997;127:910–7.
7 Edie E. Health examinations past and present and their promotion in
Pennsylvania. Am J Publ Health. 1925;15:602–6.
8 Fisk EC, Crawford JR. How to Make the Periodic Health Examination;
A Manual of Procedure. New York: Macmillan; 1927.
9 Knight A. The value of the periodic examinations in life insurance poli-
cyholders. Proceedings of the Association of Life Insurance Medical
Directors of America 1921–22;8:25.
10 Emerson H. Periodic medical examinations of apparently healthy per-
sons. JAMA. 1923;80:1376–81.
11 Wilson JMG, Jungner G. Principles and Practice of Screening for
Disease. Geneva: World Health Organization; 1968
12 Frame PS, Carlson SJ. A critical review of periodic health screening us-
ing specific screening criteria. Part 4: selected miscellaneous diseases.
J Fam Pract. 1975;2:283–9.
13 Frame PS, Carlson SJ. A critical review of periodic health screening us-
ing specific screening criteria. 3. Selected diseases of the genitourinary
system. J Fam Pract. 1975;2:189–94.
14 Frame PS, Carlson SJ. A critical review of periodic health screening
using specific screening criteria. Part 2: Selected endocrine, metabolic
and gastrointestinal diseases. J Fam Pract. 1975;2:123–9.
15 Frame PS, Carlson SJ. A critical review of periodic health screening us-
ing specific screening criteria. Part 1: Selected diseases of respiratory,
cardiovascular, and central nervous systems. J Fam Pract.
1975;2:29–36.
16 The periodic health examination. Canadian Task Force on the Periodic
Health Examination. Can Med Assoc J. 1979;121:1193–254.
17 U.S. Preventive Service Task Force. Guide to clinical preventive ser-
vices: an assessment of the effectiveness of 169 interventions: report
of the U.S. Preventive Services Task Force. Baltimore: Williams &
Wilkins; 1989
18 U.S. Preventive Service Task Force [Internet]. ht-
tp://www.uspreventiveservicetaskforce.org/congressrep.htm
19 U.S. Preventive Service Task Force [Internet]. ht-
tp://www.uspreventiveservicestaskforce.org/uspstf/grades.htm
20 Swiss Medical Board [Internet]. http://www.medical-board.ch.
21 Tengs TO, Adams ME, Pliskin JS, Safran DG, Siegel JE, Weinstein
MC, et al. Five-hundred life-saving interventions and their cost-effect-
iveness. Risk Anal. 1995;15:369–90.
22 Moyer VA. Behavioral counseling interventions to promote a healthful
diet and physical activity for cardiovascular disease prevention in
adults: U.S. Preventive Services Task Force recommendation state-
ment. Ann Intern Med. 2012;157:367–71.
23 U.S. Preventive Service Task Force. Behavioral counseling in primary
care to promote a healthy diet: recommendations and rationale. Am J
Prev Med. 2003;24:93–100.
24 Stead LF, Buitrago D, Preciado N, Sanchez G, Hartmann-Boyce J, Lan-
caster T. Physician advice for smoking cessation. Cochrane Database
Syst Rev 2013;5:CD000165
25 Bundesamt für Gesundheit [Internet]. http://www.bag.admin.ch.
26 Schroeder SA. What to do with a patient who smokes. JAMA: the
journal of the American Medical Association. 2005;294:482–7.
27 Counseling and interventions to prevent tobacco use and tobacco-
caused disease in adults and pregnant women: U.S. Preventive Services
Task Force reaffirmation recommendation statement. Ann Intern Med.
2009;150:551–5.
28 Fiore MC, Baker TB. Clinical practice. Treating smokers in the health
care setting. N Engl J Med. 2011;365:1222–31.
29 Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of
death in the United States, 2000. JAMA: the journal of the American
Medical Association 2004;291:1238–45.
30 Bertholet N, Daeppen JB, Wietlisbach V, Fleming M, Burnand B. Re-
duction of alcohol consumption by brief alcohol intervention in primary
care: systematic review and meta-analysis. Arch Intern Med.
2005;165:986–95.
31 Kaner E, Bland M, Cassidy P, Coulton S, Deluca P, Drummond C, et
al. Screening and brief interventions for hazardous and harmful alco-
hol use in primary care: a cluster randomised controlled trial protocol.
BMC public health. 2009;9:287.
32 Fleming MF, Mundt MP, French MT, Manwell LB, Stauffacher EA,
Barry KL. Brief physician advice for problem drinkers: long-term effic-
acy and benefit-cost analysis. Alcohol Clin Exp Res. 2002;26:36–43.
33 Moyer VA. Screening and behavioral counseling interventions in
primary care to reduce alcohol misuse: U.S. preventive services task
force recommendation statement. Ann Intern Med. 2013;159:210–8.
34 Babor TF, Higgins-Biddle JC, Saunders JB, Monteiro, MG. Audit-
The Alcohol Use Disorders Identification Test. Guidelines for Use in
Primary Care. Geneva: World Health Organization; 2001.
35 Maisto SA, Saitz R. Alcohol use disorders: screening and diagnosis.
The American journal on addictions / American Academy of Psychiat-
rists in Alcoholism and Addictions 2003;12(Suppl 1):S12–25.
36 Behavioral counseling to prevent sexually transmitted infections: U.S.
Preventive Services Task Force recommendation statement. Ann Intern
Med. 2008;149:491–496, W495.
37 Kamb ML, Fishbein M, Douglas JM, Jr., Rhodes F, Rogers J, Bolan G,
et al. Efficacy of risk-reduction counseling to prevent human immun-
odeficiency virus and sexually transmitted diseases: a randomized con-
trolled trial. Project RESPECT Study Group. JAMA. 1998;280:1161–7.
38 Lin JS, Whitlock E, O'Connor E, Bauer V. Behavioral counseling to pre-
vent sexually transmitted infections: a systematic review for the U.S.
Preventive Services Task Force. Ann Intern Med. 2008;149:497–508,
W496–499.
39 Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The
efficacy of influenza vaccine in elderly persons. A meta-analysis and
review of the literature. Ann Intern Med. 1995;123:518–27.
Review article: Current opinion Swiss Med Wkly. 2015;145:w14075
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 9 of 11
40 Gardner P, Schaffner W. Immunization of adults. N Engl J Med.
1993;328:1252–8.
41 Eng P, Lim LH, Loo CM, Low JA, Tan C, Tan EK, et al. Role of
pneumococcal vaccination in prevention of pneumococcal disease
among adults in Singapore. Int J Gen Med. 2014;7:179–91.
42 Australian Government- The department of health [Internet]. ht-
tp://www.immunise.health.gov.au.
43 Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et
al. 2013 ESH/ESC Guidelines for the management of arterial hyperten-
sion: the Task Force for the management of arterial hypertension of the
European Society of Hypertension (ESH) and of the European Society
of Cardiology (ESC). J Hypertens. 2013;31:1281–357.
44 The Seventh Report of the Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda
(MD); 2004.
45 Screening for high blood pressure: U.S. Preventive Services Task Force
reaffirmation recommendation statement. Ann Intern Med.
2007;147:783–6.
46 Screening for abdominal aortic aneurysm: recommendation statement.
Ann Intern Med. 2005;142:198–202.
47 Fleming C, Whitlock E, Beil T, Lederle F. Screening for Abdominal
Aortic Aneurysm: A Best-Evidence Systematic review for the U.S. Pre-
ventive Service Task Force. AHRQ Pub No 05–0569–B 2005.
48 Flegal KM, Graubard BI, Williamson DF, Gail MH. Cause-specific
excess deaths associated with underweight, overweight, and obesity.
JAMA. 2007;298:2028–37.
49 Barton M. Screening for obesity in children and adolescents: US Pre-
ventive Services Task Force recommendation statement. Pediatrics.
2010;125:361–7.
50 Moyer VA. Screening for and management of obesity in adults: U.S.
Preventive Services Task Force recommendation statement. Ann Intern
Med. 2012;157:373–8.
51 Helfand M, Carson S. Screening for Lipid Disorders in Adults: Select-
ive Update of 2001 U.S. Preventive Service Task Force Review. AHRQ
Publication No 08–05114–EF-1 2008
52 Swiss Atherosclerosis Association [Internet]. http://www.agla.ch.
53 Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR,
Wiklund O, et al. ESC/EAS Guidelines for the management of dyslip-
idaemias: the Task Force for the management of dyslipidaemias of the
European Society of Cardiology (ESC) and the European Atheroscler-
osis Society (EAS). Eur Heart J. 2011;32:1769–818.
54 Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA,
et al. Primary prevention of acute coronary events with lovastatin in
men and women with average cholesterol levels: results of AFCAPS/
TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention
Study. JAMA. 1998;279:1615–22.
55 Doser Joz-Roland N, Büla C, Rodondi N. Faut-il traiter les dyslip-
idémies chez les personnes âgées et très âgées? Rev Med Suisse.
2009;5:2211–8.
56 Ray KK, Seshasai SR, Erqou S, Sever P, Jukema KW, Ford I, et al. Stat-
ins and all-cause mortality in high-risk primary prevention: a meta-ana-
lysis of 11 randomized controlled trials involving 65,229 participants.
Arch Intern Med. 2010;170:1024–31.
57 Screening for osteoporosis: U.S. preventive services task force recom-
mendation statement. Ann Intern Med. 2011;154:356–64.
58 FRAX- WHO Rechnet zur Bestimmung des Frakturrisikos [Internet].
http://www.shef.ac.uk/FRAX/?lang=de.
59 National Osteoporosis Foundation. Clinician's Guide to Prevention and
Treatment of Osteoporosis. In. Washington, DC: National Osteoporosis
Foundation; 2014
60 Moyer VA. Vitamin D and calcium supplementation to prevent fractures
in adults: U.S. Preventive Services Task Force recommendation state-
ment. Ann Intern Med. 2013;158:691–6.
61 Screening for depression in adults: U.S. preventive services task force
recommendation statement. Ann Intern Med. 2009;151:784–92.
62 Whooley MA, Avins AL, Miranda J, Browner WS. Case-finding instru-
ments for depression. Two questions are as good as many. J Gen Intern
Med. 1997;12:439–45.
63 Screening for colorectal cancer: U.S. Preventive Services Task Force
recommendation statement. Ann Intern Med. 2008;149:627–37.
64 Hewitson P, Glasziou P, Irwig L, Towler B, Watson E. Screening for
colorectal cancer using the faecal occult blood test, Hemoccult. Co-
chrane Database Syst Rev 2007:CD001216
65 Whitlock EP, Lin JS, Liles E, Beil TL, Fu R. Screening for colorectal
cancer: a targeted, updated systematic review for the U.S. Preventive
Services Task Force. Ann Intern Med. 2008;149:638–58.
66 Manser CN, Bachmann LM, Brunner J, Hunold F, Bauerfeind P, Marbet
UA. Colonoscopy screening markedly reduces the occurrence of colon
carcinomas and carcinoma-related death: a closed cohort study.
Gastrointest Endosc. 2012;76:110–7.
67 Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global can-
cer statistics. CA Cancer J Clin. 2011;61:69–90.
68 Andrae B, Andersson TM, Lambert PC, Kemetli L, Silfverdal L,
Strander B, et al. Screening and cervical cancer cure: population based
cohort study. BMJ. 2012;344:e900.
69 Johannesson G, Geirsson G, Day N. The effect of mass screening in
Iceland, 1965–74, on the incidence and mortality of cervical carcinoma.
Int J Cancer. 1978;21:418–25.
70 Moyer VA. Screening for cervical cancer: U.S. Preventive Services
Task Force recommendation statement. Ann Intern Med.
2012;156:880–891, W312.
71 Screening for type 2 diabetes mellitus in adults: U.S. Preventive Ser-
vices Task Force recommendation statement. Ann Intern Med.
2008;148:846–54.
72 Standards of medical care in diabetes – 2014. Diabetes Care.
2014;37(Suppl 1):S14–80.
73 Moyer VA. Screening for coronary heart disease with electrocardio-
graphy: U.S. Preventive Services Task Force recommendation state-
ment. Ann Intern Med. 2012;157:512–8.
74 Karius P, Schuetz GM, Schlattmann P, Dewey M. Extracardiac findings
on coronary CT angiography: a systematic review. J Cardiovasc Com-
put Tomogr. 2014;8:174–182 e171–176.
75 Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick
JI, et al. Clinical practice guidelines for hypothyroidism in adults: co-
sponsored by the American Association of Clinical Endocrinologists
and the American Thyroid Association. Thyroid. 2012;22:1200–35.
76 Aoki Y, Belin RM, Clickner R, Jeffries R, Phillips L, Mahaffey KR.
Serum TSH and total T4 in the United States population and their as-
sociation with participant characteristics: National Health and Nutri-
tion Examination Survey (NHANES 1999–2002). Thyroid.
2007;17:1211–23.
77 Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW,
Spencer CA, et al. Serum TSH, T(4), and thyroid antibodies in the Un-
ited States population (1988 to 1994): National Health and Nutrition
Examination Survey (NHANES III). J Clin Endocrinol Metab.
2002;87:489–99.
78 Screening for thyroid disease: recommendation statement. Ann Intern
Med. 2004;140:125–7.
79 Gencer B, Collet TH, Virgini V, Bauer DC, Gussekloo J, Cappola AR, et
al. Subclinical thyroid dysfunction and the risk of heart failure events:
an individual participant data analysis from 6 prospective cohorts. Cir-
culation. 2012;126:1040–9.
80 Rodondi N, den Elzen WP, Bauer DC, Cappola AR, Razvi S, Walsh JP,
et al. Subclinical hypothyroidism and the risk of coronary heart disease
and mortality. JAMA. 2010;304:1365–74.
81 Selmer C, Olesen JB, Hansen ML,von Kappelgaard LM, Madsen JC,
Hansen PR et al. Subclinical and overt thyroid dysfunction and risk of
all-cause mortality and cardiovascular events: a large population study.
J Clin Endocrinol Metab. 2014;99:2372–82.
82 Moyer VA. Screening for lung cancer: U.S. Preventive Services Task
Force recommendation statement. Ann Intern Med. 2014;160:330–8.
83 American Cancer Society. Cancer Facts & Figures 2013. In. Atlanta,
GA: American Cancer Society; 2013.
84 Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom
RM, et al. Reduced lung-cancer mortality with low-dose computed
tomographic screening. N Engl J Med. 2011;365:395–409.
Review article: Current opinion Swiss Med Wkly. 2015;145:w14075
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 10 of 11
85 Screening for breast cancer: U.S. Preventive Services Task Force re-
commendation statement. Ann Intern Med. 2009;151:716–26, W-236.
86 Biller-Andorno N, Juni P. Abolishing mammography screening pro-
grams? A view from the Swiss Medical Board. N Engl J Med.
2014;370:1965–7.
87 Gotzsche PC, Jorgensen KJ. Screening for breast cancer with mammo-
graphy. Cochrane Database Syst Rev 2013;6:CD001877.
88 Howladder N, Noone A, Krapcho M, Neyman N, Aminou R, Waldron
W, et al. SEER Cancer Statistics Review, 1975–2008, National Cancer
Institute. In. Bethesda, MD; 2011.
89 Gasser T, Iselin C, Jichlinski P, Kreienbühl B, Merz V, Recker F, et al.
PSA-Bestimmung – Empfehlungen der Schweizerischen Gesellschaft
für Urologie (SGU). Schweiz Med Forum. 2012;12:126–8.
90 Moyer VA. Screening for prostate cancer: U.S. Preventive Services
Task Force recommendation statement. Ann Intern Med.
2012;157:120–34.
91 Croswell JM, Kramer BS, Kreimer AR, Prorok PC, Xu JL, Baker SG,
et al. Cumulative incidence of false-positive results in repeated, mul-
timodal cancer screening. Ann Fam Med. 2009;7:212–22.
92 Raaijmakers R, Kirkels WJ, Roobol MJ, Wildhagen MF, Schrder FH.
Complication rates and risk factors of 5802 transrectal ultrasound-
guided sextant biopsies of the prostate within a population-based
screening program. Urology. 2002;60:826–30.
93 Chou R, Croswell JM, Dana T, Bougatsos C, Blazina I, Fu R, et al.
Screening for prostate cancer: a review of the evidence for the U.S. Pre-
ventive Services Task Force. Ann Intern Med. 2011;155:762–71.
94 Chou R, Dana T, Bougatsos C, Fu R, Blazina I, Gleitsmann K, Bruin
Rugge J. Treatments for Localized Prostate Cancer: Systematic Review
to Update the 2002 U.S. Preventive Services Task Force Recommenda-
tion. AHRQ Pub No 12–05161–EF-1 2011.
95 Hunziker S, Schlapfer M, Langewitz W, Kaufmann G, Nuesch R, Bat-
tegay E, Zimmerli L. Open and hidden agendas of “asymptomatic” pa-
tients who request check-up exams. BMC Fam Pract. 2011;12:22.
96 Brody DS, Miller SM, Lerman CE, Smith DG, Lazaro CG, Blum MJ.
The relationship between patients' satisfaction with their physicians and
perceptions about interventions they desired and received. Med Care.
1989;27:1027–35.
97 Jackson JL, Kroenke K. Patient satisfaction and quality of care. Mil
Med. 1997;162:273–7.
98 Joos SK, Hickam DH, Borders LM. Patients’ desires and satisfaction in
general medicine clinics. Public Health Rep. 1993;108:751–9.
99 Kravitz RL, Callahan EJ, Paterniti D, Antonius D, Dunham M, Lewis
CE. Prevalence and sources of patients’ unmet expectations for care.
Ann Intern Med. 1996;125:730–7.
100 Kravitz RL, Cope DW, Bhrany V, Leake B. Internal medicine patients'
expectations for care during office visits. J Gen Intern Med.
1994;9:75–81.
101 Howard-Tripp M. Should we abandon the periodic health examina-
tion?: YES. Can Fam Physician. 2011;57:158–6.
102 Rank B. Executive physicals – bad medicine on three counts. N Engl J
Med. 2008;359:1424–5.
103 Boulware LE, Marinopoulos S, Phillips KA, Hwang CW, Maynor K,
Merenstein D, et al. Systematic review: the value of the periodic health
evaluation. Ann Intern Med. 2007;146:289–300.
104 Mavriplis CA. Should we abandon the periodic health examination?:
NO. Can Fam Physician. 2011;57:159–61.
105 Yarnall KS, Pollak KI, Ostbye T, Krause KM, Michener JL. Primary
care: is there enough time for prevention? Am J Public Health.
2003;93:635–41.
106 Krogsboll LT, Jorgensen KJ, Gronhoj Larsen C, Gotzsche PC. General
health checks in adults for reducing morbidity and mortality from dis-
ease. Cochrane Database Syst Rev 2012;10:CD009009.
107 Cass RM. General health checks in adults. JAMA Intern Med.
2013;173:1657–8.
108 Prochazka AV, Lundahl K, Pearson W, Oboler SK, Anderson RJ.
Support of evidence-based guidelines for the annual physical exam-
ination: a survey of primary care providers. Arch Intern Med.
2005;165:1347–52.
109 American Board of Internal Medicine Foundation [Internet]. ht-
tp://www.choosingwisely.org.
110 Gaspoz J. Die SGIM startet ihre Kampagne “Smarter Medicine” mit
der ersten “Top-5–Liste” der Schweiz. Schweizerische Ärztezeitung
2014;95:765.
111 U.S. Preventive Service Task Force [Internet]. ht-
tp://www.uspreventiveservicestaskforce.org/recommendations.htm
Review article: Current opinion Swiss Med Wkly. 2015;145:w14075
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 11 of 11
